OLD Category: Oncology

Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

• Paik P.K. et al.,

Identifying Etiologically Distinct Sub-Types of Cancer: A Demonstration Project Involving Breast Cancer

• Begg C.B. et al.,

Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay

• Park K. et al.,

The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models

• Garcia P.L. et al.,

Molecular Heterogeneity in a Patient-Derived Glioblastoma Xenoline Is Regulated by Different Cancer Stem Cell Populations

• Garner J.M. et al.,

Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis

• Walter R.F. et al.,

The PTEN-AKT-mTOR/RICTOR Pathway in Nasal Natural Killer Cell Lymphoma Is Activated by miR-494-3p via PTEN But Inhibited by miR-142-3p via RICTOR

• Chen H-H. et al.,

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients

• Lee E.Q. et al.,

Postoperative Prognosis Prediction of Pancreatic Cancer With Seven MicroRNAs

• Lee K.H. et al.,

MerTK is a novel therapeutic target in gastric cancer

• Yi J.H. et al.,

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer

• Bosch A. et al.,

Enhanced GAB2 expression is associated with improved survival in high-grade serous ovarian cancer and sensitivity to PI3K inhibition

• Davis S.J. et al.,